News

Qiagen and Bayer team up for CDx
Enlarge image

PharmaNetherlandsGermany

Qiagen and Bayer team up for CDx

26.10.2012 - Pharma giant Bayer Healthcare and diagnostics specialist Qiagen N.V.
have forged an alliance in the field of companion diagnostics (CDx).

Initially, the joint efforts will concentrate on several types of solid tumours. But the agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology. The targeted companion diagnostics will be designed to run on Qiagen’s QIAsymphony line of automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

„As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of Qiagen. Companion diagnostics guide treatment decisions with medications for cancers or other diseases by unlocking molecular information from each patient's tumour genome. „This helps to design more efficient clinical trials and to increase the overall probability of therapeutic success for patients suffering from cancer," said Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare.

Qiagen has more than 15 companion diagnostic collaborations ongoing with pharmaceutical and biotech companies. A major milestone was reached in July, on FDA approval of Therascreen RGQ PCR Kit. The companion diagnostic is used to screen for those metastatic colorectal cancer patients who most likely respond to therapy with Erbitux (cetuximab).

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/qiagen-and-bayer-team-up-for-cdx.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%

FLOP

  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%

TOP

  • 4SC5.41 EUR322.7%
  • WILEX5.25 EUR83.6%
  • PAION2.85 EUR21.3%

FLOP

  • BIOTEST72.00 EUR-25.9%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.16 EUR-17.6%

TOP

  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF647.1%
  • WILEX5.25 EUR517.6%

FLOP

  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-26.6%

No liability assumed, Date: 05.05.2015